Allarity Therapeutics (ALLR) CEO receives 200,000-share RSU equity grant

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)

Form Type

Rhea-AI Filing Summary

Jensen Thomas reported acquisition or exercise transactions in this Form 4 filing.

Allarity Therapeutics CEO Thomas Jensen received an equity grant of 200,000 shares of common stock as a compensation award. These shares are in the form of restricted stock units granted under the company’s Amended and Restated 2021 Equity Incentive Plan and were awarded at no cash cost per share.

The RSUs will vest in three equal annual installments on the first, second, and third anniversaries of the January 28, 2026 grant date, if he continues his relationship with the company through each vesting date. After this grant, Jensen holds 596,734 common shares directly.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Jensen Thomas

Role CEO

Type	Security	Shares	Price	Value
Grant/Award	Common Stock	200,000	$0.00	--

Holdings After Transaction: Common Stock — 596,734 shares (Direct, null)

Footnotes (1)

[object Object]

Key Figures

RSU grant size: 200,000 shares Grant price per share: $0.00 per share Shares held after grant: 596,734 shares +1 more

4 metrics

RSU grant size 200,000 shares Restricted stock units granted to CEO on January 28, 2026

Grant price per share $0.00 per share Stated price for RSU acquisition

Shares held after grant 596,734 shares CEO’s direct common stock holdings following the transaction

Vesting schedule 1/3 each year over 3 years RSUs vest on first, second, and third anniversaries of grant

Key Terms

restricted stock units, Amended and Restated 2021 Equity Incentive Plan, vesting

3 terms

restricted stock units financial

"The restricted stock units, or RSUs, granted on January 28, 2026 pursuant to Allarity Therapeutics, Inc's Amended and Restated 2021 Equity Incentive Plan"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

Amended and Restated 2021 Equity Incentive Plan financial

"granted on January 28, 2026 pursuant to Allarity Therapeutics, Inc's Amended and Restated 2021 Equity Incentive Plan"

vesting financial

"will vest in equal one-third installments on the first, second, and third anniversary of the grant"

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

Form 4 Insider Transactions: What Each Field Means →

05/14/2026 - 11:48 AM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Jensen Thomas

(Last)

(First)

(Middle)

C/O ALLARITY THERAPEUTICS, INC.

123 E TARPON AVE

(Street)

TARPON SPRINGS

FLORIDA

34689

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Allarity Therapeutics, Inc. [ ALLR ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	CEO

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
01/28/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	01/28/2026		A		200,000⁽¹⁾	A	$0	596,734	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)

Explanation of Responses:

1. The restricted stock units, or RSUs, granted on January 28, 2026 pursuant to Allarity Therapeutics, Inc's Amended and Restated 2021 Equity Incentive Plan, will vest in equal one-third installments on the first, second, and third anniversary of the grant, subject to the Reporting Person's continued relationship with the Issuer through each such date.

	/s/ Thomas Jensen	05/14/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What insider transaction did Allarity Therapeutics (ALLR) report for its CEO?

Allarity Therapeutics reported that CEO Thomas Jensen received a grant of 200,000 restricted stock units. These RSUs are a compensation award, not an open-market purchase, and increase his direct common stock holdings to 596,734 shares following the transaction.

How many Allarity Therapeutics (ALLR) shares did the CEO acquire in this Form 4?

The CEO acquired 200,000 shares of Allarity Therapeutics in the form of restricted stock units. These RSUs were granted at a stated price of $0.00 per share and vest over three years, subject to his continued service with the company.

Is the Allarity Therapeutics (ALLR) CEO Form 4 a stock purchase or a grant?

The Form 4 reflects a stock grant, not a market purchase. CEO Thomas Jensen received 200,000 restricted stock units as a compensation award under Allarity’s Amended and Restated 2021 Equity Incentive Plan, with no cash paid per share in the transaction.

What are the vesting terms of the Allarity Therapeutics (ALLR) CEO RSU grant?

The RSU grant vests in three equal installments over three years. One-third of the 200,000 restricted stock units will vest on each of the first, second, and third anniversaries of the January 28, 2026 grant date, contingent on continued service.

How many Allarity Therapeutics (ALLR) shares does the CEO hold after this grant?

Following the RSU grant, CEO Thomas Jensen directly holds 596,734 shares of Allarity Therapeutics common stock. This total includes the newly awarded 200,000 restricted stock units reported in the Form 4 insider transaction filing.

Under which plan were the Allarity Therapeutics (ALLR) CEO RSUs granted?

The CEO’s restricted stock units were granted under Allarity Therapeutics’ Amended and Restated 2021 Equity Incentive Plan. This equity plan provides for stock-based awards to executives and other participants, aligning their compensation with long-term company performance.